SCHEMBL423275

SCHEMBL423275

CCOC(=O)OCC(=O)[C@@]1(OC(=O)OCC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 11/20 0.89
PGR P06401 7/20 0.89
HIF1A Q16665 5/20 0.89
LMNA P02545 3/20 0.89
CYP3A4 P08684 2/20 0.89
USP2 O75604 1/20 0.89
CYP2D6 P10635 1/20 0.89
CYP2C9 P11712 1/20 0.89
ABCB11 O95342 2/20 0.78
NR1I2 O75469 2/20 0.78
ABCC3 O15438 1/20 0.78
NR3C2 P08235 3/20 0.60
HSD17B10 Q99714 2/20 0.60
AR P10275 2/20 0.60
TNF P01375 1/20 0.60
IL6 P05231 1/20 0.60
SERPINA6 P08185 1/20 0.60
GLUL P15104 1/20 0.60
ADAM17 P78536 1/20 0.60
GPBAR1 Q8TDU6 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11425522 1.00 NR3C1 (0.89) NR3C1PGRHIF1ALMNACYP3A4
SCHEMBL11424251 0.96 NR3C1 (0.83) NR3C1PGRHIF1ALMNACYP3A4
SCHEMBL11425125 0.96 NR3C1 (0.83) NR3C1PGRHIF1ALMNACYP3A4
SCHEMBL11432971 0.96 NR3C1 (0.85) NR3C1PGRHIF1ALMNACYP3A4
SCHEMBL11425650 0.96 NR3C1 (0.83) NR3C1PGRHIF1ALMNACYP3A4
SCHEMBL11424569 0.95 NR3C1 (0.82) NR3C1PGRHIF1ALMNACYP3A4
SCHEMBL11422242 0.95 NR3C1 (0.82) NR3C1PGRHIF1ALMNACYP3A4
SCHEMBL11433960 0.95 NR3C1 (0.81) NR3C1PGRHIF1ALMNACYP3A4
SCHEMBL11433637 0.95 NR3C1 (0.81) NR3C1PGRHIF1ALMNACYP3A4
Prednicarbate SCHEMBL5483489 0.94 NR3C1 (1.00) NR3C1PGRHIF1ALMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160058874-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2016-03-03 US disclosed
US-20160058874-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2016-03-03 US disclosed
US-20150005230-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2015-01-01 US disclosed
US-20150005230-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2015-01-01 US disclosed
US-20140328918-A1 METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS CERULEAN PHARMA INC. (US) 2014-11-06 US disclosed
US-20140328918-A1 METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS CERULEAN PHARMA INC. (US) 2014-11-06 US disclosed
US-20140255374-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE CERULEAN PHARMA INC. (US) 2014-09-11 US disclosed
US-20140255374-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE CERULEAN PHARMA INC. (US) 2014-09-11 US disclosed
WO-2013116200-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2013-08-08 WO disclosed
US-20130196906-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2013-08-01 US disclosed
US-20130196906-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2013-08-01 US disclosed
US-20120064107-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE CERULEAN PHARMA INC. (US) 2012-03-15 US disclosed
US-20120064107-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE CERULEAN PHARMA INC. (US) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196906-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC NR3C1 598/4885PGR 3603/4885HIF1A 4431/4885
US-20140255374-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE PHOSPHO1, SGMS1, SGMS2 NR3C1 2698/4885PGR 2999/4885HIF1A 4142/4885
US-20120064107-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE PHOSPHO1, SGMS1, SGMS2 NR3C1 2698/4885PGR 2999/4885HIF1A 4142/4885
US-20140328918-A1 METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS HLA-DRB1, TSG101, IAPP NR3C1 726/4885PGR 3157/4885HIF1A 2705/4885
US-20150005230-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC NR3C1 598/4885PGR 3603/4885HIF1A 4431/4885
US-20160058874-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC NR3C1 598/4885PGR 3603/4885HIF1A 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.